Edit |   |
---|---|
Product Name | Ly-49H Antibody Kit, anti-mouse, FITC, REAlease® |
Description | Ly-49H Antibody Kit, anti-mouse, FITC, REAlease®. Clone REAL196 is an antibody fragment derived from the full Ly-49H antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL196 recognizes the mouse lymphocyte antigen 49H (Ly-49H) which is also known as killer cell lectin-like receptor 8, Klra8, or Cmv-1. REAL196 does not crossreact with related molecules like Ly-49A, C, D, or G2. Ly-49H is a member of the C-type lectin Ly-49 multigene family and is expressed by C57BL/6 and NWNA but not by BALB/c and DBA/2 mouse natural killer (NK) cells. It recognizes a ligand from mouse cytomegalovirus (MCMV), and engagement of Ly-49H can lead to killing of MCMV-infected cells. In addition to NK cell cytotoxicity, Ly-49H has a crucial role in supporting NK cell proliferation to prevent immunopathology caused by the adaptive immune system. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
Size | 100 tests |
Concentration | 1:50 |
Applications | Flow cytometry |
Other Names | Klra8, Cmv-1, Cmv1 |
Gene, Accession, CAS # | n/a |
Catalog # | 130-122-613 |
Price | $117 |
Order / More Info | Ly-49H Antibody Kit, anti-mouse, FITC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Smith, K. M. et al. (1989) Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 161: 7-10. | Seung-Hwan, L. et al. (2003) Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J. Exp. Med. 197 (4): 515-526. | Seung-Hwan, L. et al. (2009) Activating receptors promote NK cell expansion for maintenance, IL10 production, and CD8 T cell regulation during viral infection. J. Exp. Med. 206: 2235-2251. |